drugset
drugset / Trial / NCT05580991

Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors

NCT05580991 ↗

Phase 1 Active not recruiting 27 enrolled Canwell Biotech Limited
NaSingle-groupOpen-labelTreatment

Summary

To evaluate CAN1012 when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.

Timeline

Start
2022-09-09
Primary completion
2025-06-30
Completion
2025-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CAN1012 Unknown — Other

Indications

neoplasm